EFFORT: Phase II Study of the WEE1 Inhibitor Adavosertib ± Olaparib in PARPi-Resistant Ovarian Cancer

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2021, from Clinical Care Options (CCO)

Jubilee Brown, MD Melissa M. Hardesty, MD, MPH Alexandra Leary, MD, PhD Domenica Lorusso, MD, PhD Ursula Matulonis, MD David Scott Miller, MD, FACOG, FACS Released: September 15, 2021

Gain key clinical insights quickly with this short slideset from CCO on the latest treatment, challenges and future directions for the management of ovarian cancer using PARPi.

Nicoletta Colombo, MD Philipp Harter, MD, PhD Alexandra Leary, MD, PhD Released: September 10, 2021

Downloadable slideset on current advances in PARP inhibition in ovarian cancer from Clinical Care Options (CCO)

Nicoletta Colombo, MD Released: September 3, 2021

Downloadable slideset on a clinical case of PARP inhibition in a patient with ovarian cancer from Clinical Care Options (CCO)

Philipp Harter, MD, PhD Released: September 3, 2021